THERAPY DOSSIER · th-1fd188f6396d

Cyclic helix B peptide (CHBP)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28826163 ↗2017Reported benefit

Protective effects of cyclic helix B peptide on aristolochic acid induced acute kidney injury.

MouseChemical/toxinBALB/cMalen = Four treatment groups; group sizes not stated in the abstra…4 nmol/kg and 8 nmol/kg

Model: Acute kidney injury induced by aristolochic acid at 10 mg/kg

CHBP dose-dependently lowered blood urea nitrogen and serum creatinine, improved tubular injury and inflammatory infiltration, reduced apoptotic and active caspase-3 positive cells, inhibited caspase-3 and caspase-9 and increased bcl-2 and bcl-xl expression.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…